Key Highlights
- Johnson & Johnson MedTech to acquire V-Wave Ltd. for $600M upfront.
- Potential milestone payments could reach up to $1.1 billion.
- Acquisition enhances Johnson & Johnson’s cardiovascular disease treatment portfolio.
- V-Wave’s Ventura® Interatrial Shunt targets heart failure with reduced ejection fraction (HFrEF).
Source: Business Wire
Notable Quote
- “We are very pleased that Paul is joining PepGen at such an important time for the Company. Throughout his career, Paul has served in leadership roles across both large and small publicly traded biopharmaceutical companies, with notable accomplishments including five IND approvals, six global regulatory launches, and nine commercial product launches.” — James McArthur, Ph.D., President and CEO at PepGen
SoHC's Take
The appointment of Dr. Paul Streck as EVP and Head of Research & Development marks a significant strategic move for PepGen Inc. His extensive experience in drug development and regulatory leadership, particularly in the realm of biopharmaceuticals, aligns well with PepGen’s mission to revolutionize treatments for severe neuromuscular and neurological diseases. Dr. Streck’s proven track record of leading clinical trials and product launches will undoubtedly propel PepGen’s innovative pipeline forward, reinforcing its position as a leader in oligonucleotide therapy.
